LEMS
MCID: LMB002
MIFTS: 51

Lambert-Eaton Myasthenic Syndrome (LEMS)

Categories: Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lambert-Eaton Myasthenic Syndrome

MalaCards integrated aliases for Lambert-Eaton Myasthenic Syndrome:

Name: Lambert-Eaton Myasthenic Syndrome 11 52 58 75 53 43 14 71 33
Lambert-Eaton Syndrome 11 75 31 33
Eaton-Lambert Syndrome 11 33
Lems 11 19
Myasthenic-Myopathic Syndrome of Lambert-Eaton 19
Lems - [lambert-Eaton Myasthenic Syndrome] 33
Myasthenic Syndrome of Lambert-Eaton 19
Lambert Eaton Myasthenic Syndrome 19
Eaton Lambert Syndrome 19
Lambert Eaton Syndrome 19

Characteristics:


Prevelance:

<1/1000000 (Netherlands) 1-9/100000 (Europe) 1-9/1000000 (Worldwide) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:0050214
ICD9CM 34 358.3
MeSH 43 D015624
NCIt 49 C3155
SNOMED-CT 68 230688006
ICD10 31 G73.1
MESH via Orphanet 44 D015624
ICD10 via Orphanet 32 G73.1
UMLS via Orphanet 72 C0022972
Orphanet 58 ORPHA43393
ICD11 33 796417193
UMLS 71 C0022972

Summaries for Lambert-Eaton Myasthenic Syndrome

NINDS: 52 Lambert-Eaton myasthenic syndrome (LEMS) is a disorder of the neuromuscular junction-the site where nerve cells meet muscle cells and help activate the muscles. It is caused by a disruption of electrical impulses between these nerve and muscle cells. LEMS is an autoimmune condition; in such disorders the immune system, which normally protects the body from foreign organisms, mistakenly attacks the body's own tissues. The disruption of electrical impulses is associated with antibodies produced as a consequence of this autoimmunity. Symptoms include muscle weakness, a tingling sensation in the affected areas, fatigue, and dry mouth. LEMS is closely associated with cancer, in particular small cell lung cancer. More than half the individuals diagnosed with LEMS also develop small cell lung cancer. LEMS may appear up to 3 years before cancer is diagnosed.

MalaCards based summary: Lambert-Eaton Myasthenic Syndrome, also known as lambert-eaton syndrome, is related to small cell cancer of the lung and myasthenia gravis. An important gene associated with Lambert-Eaton Myasthenic Syndrome is CACNB2 (Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2), and among its related pathways/superpathways are ERK Signaling and MAPK signaling pathway. The drugs Racephedrine and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include lung, spinal cord and dorsal root ganglion, and related phenotypes are reduced tendon reflexes and progressive proximal muscle weakness

GARD: 19 Lambert Eaton myasthenic syndrome (LEMS) is a disorder of the neuromuscular junction. The neuromuscular junction is the site where nerve cells meet muscle cells and help activate the muscles. This syndrome occurs when antibodies interfere with electrical impulses between the nerve and muscle cells. It may be associated with other autoimmune diseases, or more commonly coincide with or precede a diagnosis of cancer such as small cell lung cancer. Symptoms may include muscle weakness, a tingling sensation in the affected areas, fatigue, and dry mouth.

Disease Ontology: 11 A neuromuscular junction disease that is characterized by an abnormality of acetylcholine (ACh) release at the neuromuscular junction which results from an autoimmune attack against voltage-gated calcium channels (VGCC) on the presynaptic motor nerve terminal.

Orphanet: 58 Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune, presynaptic disorder of neuromuscular transmission characterized by fluctuating muscle weakness and autonomic dysfunction frequently associated with small-cell lung cancer (SCLC).

Wikipedia: 75 Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder characterized by muscle weakness... more...

Related Diseases for Lambert-Eaton Myasthenic Syndrome

Diseases related to Lambert-Eaton Myasthenic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
# Related Disease Score Top Affiliating Genes
1 small cell cancer of the lung 32.1 GRP ENO2 ELAVL4
2 myasthenia gravis 31.5 TTN TNF MUSK IL10 HLA-B
3 autoimmune disease 31.2 TTN TNF MUSK IL10 HLA-B
4 thymoma 31.0 TTN TNF IL10 AMPH
5 respiratory failure 30.9 TTN TNF MUSK IL10
6 limbic encephalitis 30.9 SOX1 ELAVL3 AMPH
7 paraneoplastic cerebellar degeneration 30.9 GRP ENO2 ELAVL4 ELAVL3 CACNA1A AMPH
8 spondyloarthropathy 1 30.6 TNF IL10 HLA-B
9 neuromuscular disease 30.4 TTN SYT2 SOX1 MUSK ELAVL4 CACNA1A
10 miller fisher syndrome 30.3 TNF MUSK AMPH
11 thymus cancer 30.2 TTN MUSK AMPH
12 neuromuscular junction disease 30.2 TTN SYT2 SOX1 MUSK AMPH
13 congenital myasthenic syndrome 30.1 TTN SYT2 MUSK CACNA1A
14 myotonic dystrophy 1 29.8 TTN ELAVL4 ELAVL3
15 episodic ataxia 29.6 MUSK CACNA1B CACNA1A
16 amyotrophic lateral sclerosis 1 29.5 TNF SOX2 MUSK IL10 ELAVL4 ELAVL3
17 peripheral nervous system disease 28.8 TTN TNF SOX2 MUSK IL10 ENO2
18 paraneoplastic syndromes 11.5
19 myasthenic syndrome, congenital, 7a, presynaptic, and distal motor neuropathy, autosomal dominant 11.4
20 lung cancer 11.2
21 small cell carcinoma 11.0
22 cerebellar degeneration 11.0
23 ptosis 10.9
24 aceruloplasminemia 10.8
25 subacute cerebellar degeneration 10.7
26 myopathy 10.7
27 impotence 10.6
28 merkel cell carcinoma 10.6
29 lung cancer susceptibility 3 10.6
30 polyneuropathy 10.6
31 adenocarcinoma 10.6
32 dysautonomia 10.6
33 paresthesia 10.6
34 dermatomyositis 10.6
35 neuroendocrine carcinoma 10.6
36 lung benign neoplasm 10.6
37 myositis 10.5
38 kearns-sayre syndrome 10.5
39 cerebellar disease 10.5
40 neuropathy 10.5
41 encephalitis 10.5
42 sjogren syndrome 10.5
43 foodborne botulism 10.5
44 anhidrosis 10.5
45 autonomic neuropathy 10.5
46 limb-girdle muscular dystrophy 10.5
47 bronchus cancer 10.5
48 neuroendocrine tumor 10.5
49 squamous cell carcinoma 10.5
50 lateral sclerosis 10.5

Graphical network of the top 20 diseases related to Lambert-Eaton Myasthenic Syndrome:



Diseases related to Lambert-Eaton Myasthenic Syndrome

Symptoms & Phenotypes for Lambert-Eaton Myasthenic Syndrome

Human phenotypes related to Lambert-Eaton Myasthenic Syndrome:

58 30 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 reduced tendon reflexes 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001315
2 progressive proximal muscle weakness 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0009073
3 xerostomia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000217
4 emg: decremental response of compound muscle action potential to repetitive nerve stimulation 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003403
5 emg: repetitive nerve stimulation abnormality 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0030000
6 calcium channel antibody positivity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0030209
7 constipation 58 30 Frequent (33%) Frequent (79-30%)
HP:0002019
8 bulbar signs 58 30 Frequent (33%) Frequent (79-30%)
HP:0002483
9 impotence 58 30 Frequent (33%) Frequent (79-30%)
HP:0000802
10 small cell lung carcinoma 58 30 Frequent (33%) Frequent (79-30%)
HP:0030357
11 hypohidrosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000966
12 keratoconjunctivitis sicca 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001097
13 orthostatic hypotension due to autonomic dysfunction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004926
14 dysautonomia 58 Very frequent (99-80%)
15 abnormality of the orbital region 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 AMPH AP3B2 CACNA1A CACNA1B CACNB2 ELAVL3
2 no effect GR00402-S-2 10.18 AMPH AP3B2 CACNA1A CACNA1B CACNB2 ELAVL3

MGI Mouse Phenotypes related to Lambert-Eaton Myasthenic Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.25 AMPH AP3B2 CACNA1A CACNA1B CACNB2 ELAVL3
2 growth/size/body region MP:0005378 10.1 CACNA1A CACNA1B CACNB2 ENO2 GRP HLA-B
3 no phenotypic analysis MP:0003012 9.97 CACNA1A ERC1 HLA-B IL10 SOX1 SOX2
4 behavior/neurological MP:0005386 9.89 AMPH AP3B2 CACNA1A CACNA1B ELAVL3 ELAVL4
5 craniofacial MP:0005382 9.7 CACNB2 ENO2 IL10 SOX2 SOX3 TNF
6 mortality/aging MP:0010768 9.53 AMPH CACNA1A CACNA1B CACNB2 ELAVL3 ELAVL4

Drugs & Therapeutics for Lambert-Eaton Myasthenic Syndrome

Drugs for Lambert-Eaton Myasthenic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racephedrine Approved, Experimental Phase 1, Phase 2 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
2
Melphalan Approved Phase 2 148-82-3 4053 460612
3
Carmustine Approved, Investigational Phase 2 154-93-8 2578
4
Etoposide Approved Phase 2 33419-42-0 36462
5
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
6
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
7
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
8
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
9
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
10
Cortisone Experimental Phase 2 53-06-5 222786
11 Central Nervous System Stimulants Phase 1, Phase 2
12 Vasoconstrictor Agents Phase 1, Phase 2
13 Sympathomimetics Phase 1, Phase 2
14 Antineoplastic Agents, Hormonal Phase 2
15 Antiviral Agents Phase 2
16 Alkylating Agents Phase 2
17 Antineoplastic Agents, Alkylating Phase 2
18 Anti-Infective Agents Phase 2
19
Etoposide phosphate Phase 2 16760419
20 Antimitotic Agents Phase 2
21 Hormones Phase 2
22 Keratolytic Agents Phase 2
23 Nitrogen Mustard Compounds Phase 2
24 Hormone Antagonists Phase 2
25 Antimetabolites Phase 2
26 Antilymphocyte Serum Phase 2
27 Tubulin Modulators Phase 2
28 Thymoglobulin Phase 2
29 glucocorticoids Phase 2
30 Anti-Inflammatory Agents Phase 2
31 Dermatologic Agents Phase 2
32 Immunosuppressive Agents Phase 2
33 Immunologic Factors Phase 2
34
D-Alanine Experimental, Nutraceutical Phase 2 302-72-7, 338-69-2, 56-41-7 101757026 602 71080 5950
35
Salbutamol Approved, Vet_approved Phase 1 18559-94-9 2083
36 Adrenergic Agents Phase 1
37 Neurotransmitter Agents Phase 1
38 Bronchodilator Agents Phase 1
39 Adrenergic beta-Agonists Phase 1
40 Adrenergic Agonists Phase 1
41 Anti-Asthmatic Agents Phase 1
42 Respiratory System Agents Phase 1
43 Tocolytic Agents Phase 1
44
Amifampridine Approved, Investigational 54-96-6 5918
45 Potassium Channel Blockers

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
2 A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
3 A Phase 3, Double-blind, Outpatient Crossover Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4 Diaminopyridine Phosphate) in Patients With Congenital Myasthenic Syndromes (CMS) Completed NCT02562066 Phase 3 amifampridine phosphate;Placebo
4 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine
5 Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome Completed NCT01511978 Phase 2 Continuous 3,4-DAP;Taper 3,4-DAP to Placebo
6 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
7 Controlled Trial of 3,4-Diaminopyridine in LEMS Terminated NCT02090725 Phase 2 3-4 Diaminopyridine
8 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1 Albuterol
9 National Registry for Egyptian Pediatric Neuromuscular Diseases Unknown status NCT02124616
10 Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection: Consequences on the Severity of Myasthenic Syndrome and Reciprocal Impact of the Two Pathologies on Their Respective Treatments Unknown status NCT04695379
11 Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS) Approved for marketing NCT00872950 3,4-DIAMINOPYRIDINE
12 Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS) Approved for marketing NCT01825395 3, 4-Diaminopyridine
13 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Completed NCT00004832 3,4-diaminopyridine
14 Barriers and Facilitators to Exercise for Individuals With Autoimmune Myasthenia Gravis, Congenital Myasthenic Syndrome or Lambert-Eaton Myasthenic Syndrome in France: a Descriptive, Cross-sectional Study Completed NCT05408702
15 Retrospective Study :Describe the Changes of the Disease in Many Cases Likely to Aggravate. Completed NCT01474980
16 Congenital Muscle Disease Patient and Proxy Reported Outcome Study Recruiting NCT01403402
17 Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia Available NCT03062631 3,4-Diaminopyridine
18 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia No longer available NCT02012933 3,4-diaminopyridine
19 Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes With 3, 4-Diaminopyridine No longer available NCT01378546 3,4-diaminopyridine
20 Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome No longer available NCT01373333 3,4 DAP
21 Treatment of Lambert-Eaton Syndrome With 3, 4-Diaminopyridine No longer available NCT00704925 3, 4 DAP
22 Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine No longer available NCT00994916 3,4 diaminopyridine
23 An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Congenital Myasthenic Syndrome (CMS) No longer available NCT02189720 Amifampridine Phosphate
24 Treatment Use of 3,4-Diaminopyridine in Congenital Myasthenic Syndrome No longer available NCT01765140 3,4-diaminopyridine

Search NIH Clinical Center for Lambert-Eaton Myasthenic Syndrome

Cochrane evidence based reviews: lambert-eaton myasthenic syndrome

Genetic Tests for Lambert-Eaton Myasthenic Syndrome

Anatomical Context for Lambert-Eaton Myasthenic Syndrome

Organs/tissues related to Lambert-Eaton Myasthenic Syndrome:

MalaCards : Lung, Spinal Cord, Dorsal Root Ganglion, Skeletal Muscle, Eye, Prostate, Skin

Publications for Lambert-Eaton Myasthenic Syndrome

Articles related to Lambert-Eaton Myasthenic Syndrome:

(show top 50) (show all 1366)
# Title Authors PMID Year
1
The emerging diversity of neuromuscular junction disorders. 53 62
17915563 2007
2
Immunogenicity of P/Q-type calcium channel in small cell lung cancer: investigation of alpha1 subunit polyglutamine expansion. 53 62
10674974 1999
3
Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum. 53 62
8957009 1996
4
SOX-1 antibodies in a patient with Crohn's disease: a case report. 62
36324062 2022
5
Early vs Late Surgical Decompression for Central Cord Syndrome. 62
36169962 2022
6
Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: A case report. 62
36276497 2022
7
Paraneoplastic syndromes: A focus on pathophysiology and supportive care. 62
35916756 2022
8
Amifampridine for Lambert-Eaton myasthenic syndrome. 62
36382167 2022
9
Effects of paired stimulation with specific waveforms on cortical and spinal plasticity in subjects with a chronic spinal cord injury. 62
35277321 2022
10
The European Lambert-Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment. 62
35511347 2022
11
Natural aging course of lumbar extensor muscle mass and strength in community-dwelling older women: a 1-year prospective observational study. 62
35668336 2022
12
Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer. 62
36047125 2022
13
Progressive motor quadriparesis with wasting: a diagnostic conundrum. 62
35999018 2022
14
Plasma lncRNA LOC338963 and mRNA AP3B2 are upregulated in paraneoplastic Lambert-Eaton myasthenic syndrome. 62
35508598 2022
15
Muscle Strength and Balance as Mediators in the Association between Physical Activity and Health-Related Quality of Life in Community-Dwelling Older Adults. 62
36013095 2022
16
Machine Learning for Predicting Lower Extremity Muscle Strain in National Basketball Association Athletes. 62
35923866 2022
17
Ultrasound Measurements of Rectus Femoris and Locomotor Outcomes in Patients with Spinal Cord Injury. 62
35888161 2022
18
Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome-a case report. 62
35391602 2022
19
Long-Standing Lambert-Eaton Myasthenic Syndrome Caused by Undetectable Small-Cell Lung Cancer: Why We Should Follow-Up LEMS. 62
35885447 2022
20
Paraneoplastic syndromes in ophthalmology. 62
35292226 2022
21
Lambert-Eaton Myasthenic Syndrome Caused by Atezolizumab in a Patient with Small-cell Lung Cancer. 62
34707051 2022
22
Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer. 62
35650630 2022
23
What is in the Neuromuscular Junction Literature? 62
35608642 2022
24
A MIDDLE-AGED PATIENT WITH BILATERAL VISION LOSS AND NYCTALOPIA. 62
36007183 2022
25
Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States. 62
35740866 2022
26
Lambert-Eaton myasthenic syndrome (LEMS) in a patient with lung cancer under treatment with pembrolizumab: a case study. 62
35549636 2022
27
An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor. 62
34642096 2022
28
Outcomes of the five times sit-to-stand test could determine lower limb functions of ambulatory people with spinal cord injury only when assessed without hands. 62
32808892 2022
29
A New Score Based on the International Standards for Neurological Classification of Spinal Cord Injury for Integrative Evaluation of Changes in Sensorimotor Functions. 62
34937399 2022
30
Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases. 62
35740249 2022
31
Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength. 62
35534187 2022
32
Characterizing Natural Recovery of People With Initial Motor Complete Tetraplegia. 62
34800476 2022
33
Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors. 62
34544947 2022
34
Electrodiagnostic Evolution in a Case of Paraneoplastic Lambert-Eaton Myasthenic Syndrome in the Intensive Care Unit. 62
33845932 2022
35
Effects of Natural Products on Neuromuscular Junction. 62
34561984 2022
36
Autonomic dysfunction detected by skin sympathetic response in Lambert-Eaton myasthenic syndrome: a case report. 62
35305594 2022
37
Adaptive Remodeling of the Neuromuscular Junction with Aging. 62
35406714 2022
38
Evaluation of functional outcome and neurological recovery pattern in patients with retro-thecal tubercular epidural abscess managed at a tertiary center. 62
35241883 2022
39
Effect of Moringa stenopetala leaf extracts on the physicochemical characteristics and sensory properties of lagered beer. 62
35154687 2022
40
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. 62
35065041 2022
41
Quantitative electrophysiological assessments as predictive markers of lower limb motor recovery after spinal cord injury: a pilot study with an adaptive trial design. 62
35210402 2022
42
Effects of repetitive transcranial magnetic stimulation on recovery in lower limb muscle strength and gait function following spinal cord injury: a randomized controlled trial. 62
34504284 2022
43
Lambert-Eaton myasthenic syndrome in a young girl. 62
35228217 2022
44
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. 62
35065040 2022
45
Myasthenia gravis associated with a pelvic follicular lymphoma. 62
35027392 2022
46
Lambert-Eaton Myasthenic Syndrome in Lung Cancer. 62
35854773 2022
47
Educational Case: Lambert-Eaton syndrome. 62
35600751 2022
48
Finding the Way to Improve Motor Recovery of Patients with Spinal Cord Lesions: A Case-Control Pilot Study on a Novel Neuromodulation Approach. 62
35053862 2022
49
Lateral Corticospinal Tract and Dorsal Column Damage: Predictive Relationships With Motor and Sensory Scores at Discharge From Acute Rehabilitation After Spinal Cord Injury. 62
34371017 2022
50
Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan. 62
36110924 2022

Variations for Lambert-Eaton Myasthenic Syndrome

Expression for Lambert-Eaton Myasthenic Syndrome

Search GEO for disease gene expression data for Lambert-Eaton Myasthenic Syndrome.

Pathways for Lambert-Eaton Myasthenic Syndrome

Pathways related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 TNF SOX3 SOX21 SOX2 SOX1 MUSK
2 11.95 TNF CACNB2 CACNA1B CACNA1A
3 11.61 TNF SOX2 IL10
4 11.51 TNF IL10 HLA-B
5 11.1 CACNB2 CACNA1B CACNA1A
6 10.82 CACNB2 CACNA1B CACNA1A
7 10.4 CACNA1B CACNA1A

GO Terms for Lambert-Eaton Myasthenic Syndrome

Cellular components related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel complex GO:0005891 9.1 CACNB2 CACNA1B CACNA1A

Biological processes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anatomical structure morphogenesis GO:0009653 9.76 SOX3 SOX21 SOX2 SOX1
2 negative regulation of cytokine production involved in immune response GO:0002719 9.26 TNF IL10
3 chronic inflammatory response to antigenic stimulus GO:0002439 8.92 TNF IL10

Molecular functions related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel activity GO:0005245 9.43 CACNB2 CACNA1B CACNA1A
2 high voltage-gated calcium channel activity GO:0008331 9.1 CACNB2 CACNA1B CACNA1A

Sources for Lambert-Eaton Myasthenic Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....